If you're an Aussie investor with an eye on the healthcare sector, chances are you've heard the buzz around Neuren Pharmaceuticals Ltd and Telix Pharmaceuticals Ltd.
Neuren Pharmaceuticals is a biotechnology company specialising in developing novel treatments for neurodevelopmental disorders, those that affect children. Its flagship drug, DAYBUE, was approved by the US FDA in March 2023 as the first ever treatment for Rett syndrome, and is licensed in the US through Acadia Pharmaceuticals. According to its recent company profile, DAYBUE remains the only approved therapy for this indication.
Neuren is also progressing trials of new candidates targeting more syndromes, signalling a pipeline.
Telix Pharmaceuticals is another home-grown biotech success story, but with a different therapeutic focus. Telix develops and commercialises theranostic products using targeted radiation, with emphasis on treating and imaging cancers such as prostate, kidney, and brain tumours. The company's prostate cancer imaging agent, Illuccix, already has approvals in Australia, the US, and Canada, with the UK and Europe also on its radar.
Telix boasts a pipeline, with over 20 clinical trials underway across multiple countries and therapeutic areas.
Telix's size and global reach, plus its diverse late-stage pipeline, make it an intriguing candidate for growth investors focused on healthcare innovation.
Looking at the past month: 19 August to 17 September 2026.
The verdict comes down to momentum and growth potential—Telix's YTD return of 50.6% crushes Neuren's 10.2%, and the recent price charts show Telix enjoying much stronger investor confidence.